Literature DB >> 19067158

Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1.

Christopher A Pettigrew1, Juliet D French, Jodi M Saunus, Stacey L Edwards, Aisha V Sauer, Chanel E Smart, Therese Lundström, Christiane Wiesner, Amanda B Spurdle, Joseph A Rothnagel, Melissa A Brown.   

Abstract

Recent characterization of the mammalian transcriptome has confirmed its predicted complexity, with many loci encoding multiple splice variants and pseudogenes. The breast cancer susceptibility gene BRCA1 is a tumour suppressor gene that produces multiple functional transcripts. For example, BRCA1-IRIS is a splice variant of BRCA1, which encodes a protein that is functionally distinct from BRCA1. Here we describe the identification of ten novel Brca1 splice variants including Brca1-Iris, the mouse orthologue of human BRCA1-IRIS. We show that Brca1-Iris is differentially expressed during mammary epithelial differentiation and regulates survival of mammary epithelial cells. Another transcript, Brca1-Delta22, expressed in both mouse and human cells, was found to be defective in transcriptional activation capacity. Finally, we show that the human BRCA1 pseudogene produces a spliced pseudoBRCA1 transcript. The identification of these transcripts has implications for the understanding of the role of BRCA1 in biology and disease and for the interpretation of mouse knockout models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067158     DOI: 10.1007/s10549-008-0256-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.

Authors:  Eman Sami; Bibbin T Paul; James A Koziol; Wael M ElShamy
Journal:  Cancer Res       Date:  2020-01-07       Impact factor: 12.701

2.  Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

Authors:  Patricia Castillo; Omonigho Aisagbonhi; Cheryl C Saenz; Wael M ElShamy
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

Review 3.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

Review 4.  BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.

Authors:  Maja Sedic; Charlotte Kuperwasser
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  Regulation of the Wip1 phosphatase and its effects on the stress response.

Authors:  Julie Lowe; Hyukjin Cha; Mi-Ok Lee; Sharlyn J Mazur; Ettore Appella; Albert J Fornace
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

6.  The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.

Authors:  Yoo Jane Han; Jing Zhang; Jung-Hyun Lee; Jennifer M Mason; Olga Karginova; Toshio F Yoshimatsu; Qinyu Hao; Ian Hurley; Laia Paré Brunet; Aleix Prat; Kannanganattu V Prasanth; Michaela U Gack; Olufunmilayo I Olopade
Journal:  Cancer Res       Date:  2021-01-20       Impact factor: 13.312

7.  The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.

Authors:  Daniel Ryan; Bibbin T Paul; Jim Koziol; Wael M ElShamy
Journal:  Breast Cancer Res       Date:  2019-04-24       Impact factor: 6.466

8.  Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia.

Authors:  Carolina Cortés; Ana Lucía Rivera; David Trochez; Melissa Solarte; Daniela Gómez; Laura Cifuentes; Guillermo Barreto
Journal:  Hered Cancer Clin Pract       Date:  2019-07-15       Impact factor: 2.857

Review 9.  Preclinical mouse models for BRCA1-associated breast cancer.

Authors:  R M Drost; J Jonkers
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.